- FDA cleared 527 AI devices by Q4 2023 (FDA list).
- Echo analysis drops 90% in time, 30 to 3 minutes (Ultromics, 2023).
- $10B cardio-oncology market by 2026 (Grand View Research).
Artificial intelligence in cardio-oncology care uses 527 FDA-cleared devices to track heart risks from cancer drugs (FDA AI/ML list, Q4 2023). Ultromics' EchoGo analyzes echocardiograms for strain in 3 minutes, down 90% from 30 (Ultromics data, 2023). Caption Health enables ultrasound without experts.
Cancer therapies like immunotherapies raise cardiac risks. Startups train supervised CNNs on Mayo Clinic scans. Federated learning keeps data private across sites. NVIDIA Clara speeds GPU training.
Tech stacks cut FDA timelines from years to months.
CNNs, Transformers Raise Detection Accuracy
CNNs segment left ventricular mass in echoes. Transformers merge ECG and troponin for risk scores. Ultromics' EchoGo beats cardiologists 25% in accuracy (FDA 510(k), 2021).
Caption Health uses AI with handheld probes for bedside scans. Eko detects valve issues post-radiation via phonocardiograms. Models pull multimodal data from EHR APIs.
Google Cloud Healthcare provides pre-trained models (Google Cloud overview). Fine-tuning cuts compute 70% (Google case studies, 2023).
Synthetic Data Accelerates FDA Paths
AI creates synthetic echoes mimicking doxorubicin effects. This augments data without long collections.
AWS SageMaker tunes hyperparameters. Validation takes weeks. Federated trials enable multi-site studies.
FDA AI/ML Action Plan speeds 510(k) clearances (FDA list). Protocols allow post-market updates for CAR-T. Paths now 40% faster, saving $5M per startup (CB Insights, 2023).
- Startup: Ultromics · Modality: Echocardiography · Key Application: Strain analysis for heart failure · FDA Status: Cleared (2021)
- Startup: Caption Health · Modality: Ultrasound · Key Application: Operator-independent guidance · FDA Status: Cleared (2020)
- Startup: Eko · Modality: Phonocardiography · Key Application: Post-radiation murmur detection · FDA Status: Cleared (2022)
- Startup: Tempus · Modality: Multimodal · Key Application: Oncology risk integration · FDA Status: Pipeline
- Startup: PathAI · Modality: Pathology · Key Application: Biomarker-cardiac correlation · FDA Status: Cleared (2023)
FHIR feeds AI outputs to oncologist workflows.
FDA Rules Stress AI Transparency
FDA AI/ML plan requires model cards on biases and data. EMA adds similar rules.
Frontiers in Cardiovascular Medicine shows AI predicts trastuzumab risks 30% better than ejection fraction (Frontiers study, 2023).
Epic EHR plugins enable real-time surveillance.
AI Tracks Cardiotoxicity in Real Time
Immunotherapies cause myocarditis. Radiation damages valves. AI monitors doses via embedded models.
Apple Watch ECG apps deliver alerts. Care shifts to prevention. Market hits $10B by 2026 (Grand View Research, 2023).
VCs Fund AI Cardio-Oncology Growth
Point-of-care scores balance cancer treatment and heart risks. Hospitals pay SaaS fees at 60% margins.
Rock Health reports $2.5B VC in AI medtech (2023). Datasets build moats for Philips, GE buys.
AHA Circulation details AI-human workflows (AHA review, 2022). Explainable AI builds trust. Trials set AI as standard protocol.
Frequently Asked Questions
What is artificial intelligence in cardio-oncology care?
Artificial intelligence in cardio-oncology care uses ML to predict heart damage from cancer treatments. FDA tools like Ultromics EchoGo offer 25% better accuracy (FDA validation).
How do AI innovations accelerate oncology startup pipelines?
AI innovations accelerate oncology startup pipelines via synthetic data, federated learning. NVIDIA Clara cuts FDA clearance to months, saves $5M (CB Insights).
What startups develop AI for cardio-oncology?
Ultromics, Caption Health, Eko lead. Ultromics does echo strain; Eko phonocardiograms; all FDA-cleared.
How does FDA regulate artificial intelligence in cardio-oncology care?
FDA uses AI/ML frameworks, model cards for artificial intelligence in cardio-oncology care. Cleared 527 devices with pre-change controls (FDA Q4 2023).
